Stockwinners Market Radar for November 29, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EST Eisai and Biogen present full results for Lecanemab phase 3 study in AD - Eisai Co (ESALY) and Biogen (BIIB) "announced that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease, or AD, and mild AD with confirmed presence of amyloid pathology in the brain, were presented at the 2022 Clinical Trials on Alzheimer's Disease conference, in San Francisco, California and virtually. Mean change of CDR-SB from baseline at 18 months as the primary endpoint was 1.21 and 1.66 for lecanemab and placebo groups, respectively. Lecanemab treatment resulted in highly statistically significant results, reducing clinical decline on the global cognitive and functional scale, compared with placebo at 18 months by -0.45, representing a 27% slowing of decline. Starting as early as six months and increasing in absolute difference over time across all time points every 3 months, the treatment showed highly statistically significant changes in CDR-SB from baseline compared to placebo. All key secondary endpoints also showed highly statistically significant results compared with placebo. In the amyloid PET sub-study, treatment with lecanemab showed statistically significant reduction in amyloid plaque burden at all timepoints starting at 3 months. Mean change in Centiloids at 18 months was -55.5 and 3.6 for lecanemab and placebo groups, respectively. Lecanemab slowed decline of cognitive function by 26% on ADAS-Cog14 at 18 months n the ADCOMS assessment, lecanemab slowed disease progression by 24% at 18 months. Lecanemab slowed decline of activities of daily living by 37% on ADCS MCI-ADL at 18 months. In addition, the primary stratified analysis showed consistent results in CDR-SB, ADAS-Cog14 and ADCS MCI-ADL at 18 months of treatment with lecanemab in all subgroups of disease stage, ApoE4 status, presence or absence of concomitant approved AD symptomatic medication, and region."

18:48 EST Berry Corporation announces management changes - Berry announced the evolution of its executive team, effective January 1, 2023: Trem Smith, Berry's current Board Chairman, President and CEO, to become Executive Chairman; Berry's current COO Fernando Araujo to become CEO; the position of COO will be eliminated; Berry's current General Counsel and Corporate Secretary Danielle Hunter to become President with responsibility for the Legal, Finance, Human Resources, and Health, Safety and Environmental functions; Berry's current Chief Accounting Officer Mike Helm to become CFO, also maintaining Chief Accounting Officer designation; Cary Baetz, Berry's current CFO and member of the Board, will remain at the Company in his board role and as a special advisor helping in the transition until March 2023.

18:33 EST Raytheon Technologies awarded $114.5M Navy contract order - Raytheon Technologies was awarded a not-to-exceed $114.5M cost-plus-fixed-fee undefinitized order against a previously issued basic ordering agreement. This order provides supplies or services for design engineering, program management support, technology maturation, risk reduction, long lead material and hardware, and weapons system integration to support F135 engine enhancement efforts for the F-35 Lightning II program. Work is expected to be completed in September 2024. FY22 research, development, test and evaluation funds in the amount of $56M will be obligated at the time of award, all of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:53 EST Rolls-Royce awarded $228.09M Navy contract - Rolls-Royce was awarded a $228.09M firm-fixed-price, indefinite-delivery/indefinite-quantity contract. This contract provides for sustaining engineering and logistics support services for the KC-130J aircraft propulsion system for the Navy, Marine Corps, and Foreign Military Sales customers. Work is expected to be completed in November 2027. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. This contract was not competitively procured pursuant to 10 U.S. Code 2304 . The Naval Air Systems Command is the contracting activity.

17:45 EST AppLovin CMO Jansen sells 48,562 class A shares - In a regulatory filing, AppLovin chief marketing officer Katie Kihorany Jansen disclosed the sale of 48,562 class A common shares of the company on November 25 at a price of $14.053 per share.

17:28 EST MidWestOne CEO buys $857K in common stock - In a regulatory filing, MidWestOne disclosed that its CEO Charles Reeves bought 25K shares of common stock on November 29th in a total transaction size of $857K.

17:19 EST Wayfair reports five-day peak holiday comparable sales up low single digits - Wayfair announced strong results for the five-day peak holiday shopping period between Thanksgiving and Cyber Monday, including a low single digit sales increase in the U.S. compared to the same time period in 2021. Black Friday was the biggest sales day. In addition, repeat customers accounted for 73% of holiday orders for the five-day period, and hundreds of thousands of new customers ordered from Wayfair for the first time.

17:11 EST Cosmos Health enters development phase for CCX0722 - Cosmos Health announced that it has entered the development phase for CCX0722, an innovative product for obesity and weight management, based on the effectiveness of biocompatible 3D spatial fillers, from natural ingredients. Spatial fillers are hydrophilic biopolymer grids capable of absorbing and retaining large amounts of water or biological fluids. Administration of CCX0722 is expected to reduce food intake by increasing satiety and reducing appetite. The product is being optimized in terms of its physicochemical properties and its effects on gut microflora through a series of in vitro studies and simulations. COSMOS plans to initiate clinical intervention in the fourth quarter of 2023. The product was developed by Cloudpharm PC and collaborators states Dr. Panagiotis Zoumpoulakis, who is also the R&D Advisory Board member for Cosmos Health. Dr. Zoumpoulakis is an associate professor and Head of the department of Food Science and Technology of the University of West Attica, Greece. He holds a bachelor's degree and Ph.D. in Chemistry from the University of Patras and an MBA from the Athens University of Economics and Business. He has authored 130 peer review scientific publications and has been awarded 26 national and European grants.

17:00 EST Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi - In after-hours trading, shares are up 33% to $104.99.

16:55 EST Horizon Pharma trading resumes

16:45 EST Team names Keith Tucker as new CEO - Team appointed Keith Tucker as CEO effective as of November 22. Mr. Tucker had been serving as interimCEO since March 2022.

16:38 EST PBF Energy, PBF Logistics announce departure of CFO C. Erik Young - PBF Energy (PBF) and PBF Logistics LP (PBFX) announced that C. Erik Young, CFO, has resigned to pursue other professional opportunities. Young's resignation will be effective December 20, 2022. A search for potential internal and external candidates to replace Young will be conducted.

16:35 EST Eve Holding unable to file the Quarterly Report on Form 10-Q by prescribed date - Eve Holding announced that as previously disclosed in the Company's Notification of Late Filing on Form 12b-25, filed with the SEC on November 14, the Company has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30 by the prescribed due date because the Company requires additional time to finalize the Form 10-Q, as it is currently performing a further assessment of its condensed consolidated financial statements to determine the full extent of any adjustments in the amounts previously reported. Upon completion of such assessment, the Company also intends to file an amendment to the Company's Current Report on Form 8-K filed with the SEC on May 13, to restate its financial statements as of and for the quarter ended March 31 and the year ended December 31, 2021, as well as an amendment to the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2022 to restate its financial statements as of and for the quarter ended June 30. While the Company can provide no assurances as to timing, the Company plans to file the Form 10-Q as soon as practicably possible to regain compliance with the Listing Standard.

16:34 EST Crowdstrike falls 18% after Q3 results and guidance - Shares of Crowdstrike are down 18.4% or $25.43 afterhours at $112.57 after the company reported better than expected Q3 results but missed on Q4 revenue guidance.

16:30 EST NetApp falls 11% to $64.00 after Q2 results and FY23 guidance cut

16:26 EST Horizon Therapeutics confirms preliminary deal talks with Amgen, Janssen, Sanofi - The Board of Horizon Therapeutics (HZNP) confirms that it is engaged in highly preliminary discussions with Amgen (AMGN), Janssen Global Services (JNJ), and Sanofi (SNY) which may or may not lead to an offer being made for the entire share capital of the company. There can be no certainty that any offer will be made for the company. In accordance with Rule 2.6 of the Irish Takeover Rules, each of the Possible Offerors is required, no later than 5:00 pm (New York time) on Jan. 10, 2023, to either (i) announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Irish Takeover Rules; or (ii) announce that it does not intend to make an offer for the Company, in which case the announcement will be treated as a statement to which Rule 2.8 of the Irish Takeover Rules applies. This deadline will only be extended with the consent of the Irish Takeover Panel in accordance with Rule 2.6(c) of the Irish Takeover Rules, at the request of the company.

16:24 EST MDxHealth provides business update - MDxHealth provided clinical and reimbursement product developments, updated guidance for FY22, and initial guidance for 2023. Under the foundational LCD process recently implemented by the Molecular Diagnostics Services Program administered by Palmetto GBA, all tests within an LCD-covered indication must submit a Technical Assessment for review and consideration. The indication for use of Select mdx is covered by Medicare's foundational LCD Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer, which became effective in July. The Select mdx TA has already been submitted and we are engaged in an interactive review process with MolDX. Based on the company's most recent communication with MolDX, a final coverage decision is not expected until H1 2023. The recently released NCCN for Prostate Cancer Guideline expands the indication for use of the GPS test to include high-risk patients with localized prostate cancer. In August, mdxhealth announced that it acquired the Oncotype DX Genomic Prostate Score test from Exact Sciences, further solidifying the company's leadership in the precision diagnostics urology market. This expanded criteria to address high-risk patients provides additional validation for the clinical utility of GPS in making prostate cancer treatment decisions and enables the company to more fully serve its targeted patient population.

16:20 EST Horizon Pharma trading halted, news pending

16:18 EST Solid Power CEO Douglas Campbell to retire, David Jensen named interim CEO - Solid Power announced that Douglas Campbell has decided to retire from his role as CEO and a member of the board of directors, effective immediately. The Solid Power board has appointed David Jansen, the company's chair and president, as interim CEO. Solid Power's board of directors has commenced a search process to identify a permanent CEO with the assistance of a leading, independent executive search firm and will consider internal and external candidates.

16:13 EST Sana Biotechnology confirms program timelines and portfolio priories - Sana Biotechnology announced a portfolio prioritization designed to optimize the development of programs at or nearing clinical development, continue investments in our core research platforms and innovation, and maintain a strong balance sheet with an expected cash runway into 2025. The resulting changes include focusing its second HIP-modified allogeneic CAR T program on targeting CD22 for CD19 CAR T failures, halting further internal investment in its SC187 program and stage-gating certain platform investments based upon clinical progress in humans. The prioritization and restructuring reduced the company's headcount by approximately 15%, which gives the company the expected runway to invest in its key clinical programs over the next several years. Timelines for the company's lead programs, including time to IND and clinical data, are not expected to be impacted."We are making significant progress with our platforms to address two of the fundamental opportunities to enable greater utilization of cell engineering to treat serious diseases - overcoming immune rejection of allogeneic cells and in vivo delivery of gene modification reagents in a cell-specific manner. We look forward to generating human proof of concept starting next year and are positioning the company to invest fully based upon the clinical data," said Steve Harr, Sana's President and CEO. "Losing talented and valued colleagues is painful, and we thank them for their contributions to Sana's mission. Prioritization is important, and we will continue to make decisions based upon internal data, external evolution of the field, and the company's needed capabilities to deliver on the promise of our pipeline with important medicines for patients."

16:12 EST Fubo Sports Network now available on Amazon Freevee - Fubo Sports Network, the live, free-to-consumer TV network from FuboTV (FUBO), has launched on Amazon Freevee (AMZN). Fans can now stream Fubo Sports Network's live sports, award-winning original programming and partner content on Amazon Freevee, the streaming video service with thousands of premium movies and TV shows, including Originals and FAST channels, available anytime, for free. "With the launch of Fubo Sports Network on Amazon Freevee, we're bringing our athlete-driven programming and original series to more eyeballs than ever before," said Pamela Duckworth, head of Fubo Networks and originals, FuboTV. "There is a growing appetite for the voice of the athlete and our goal is to connect with fans wherever they choose to consume content. Platforms like Freevee allow us to do just that at no extra cost for our audiences. We're delighted to join Freevee's impressive lineup of premium channels."

16:10 EST Foot Locker announces leadership team appointments - Foot Locker announced leadership team appointments to support growth and enhance operational efficiency, as well as a planned transition of the Company's CFO. The Company's leadership changes are as follows: Frank Bracken has been named Executive Vice President and Chief Commercial Officer, effective December 1, and will continue leading Foot Locker's global retail banners, merchandising, and marketing, as well as digital, loyalty, and e-commerce. Bracken is a critical enterprise leader who has held multiple leadership roles in his more than 12 years at Foot Locker. Elliott Rodgers joins the Company as Executive Vice President and COO, effective December 1, and will oversee supply chain, information technology, and procurement. Rodgers brings to Foot Locker over 20 years of leadership experience in operations planning, supply chain, logistics, information technology, and enterprise data and analytics. He was previously an executive at Ulta Beauty, for eight years, serving as Chief Supply Chain Officer, Chief Information Officer, and Senior Vice President, Supply Chain. Andrew Page will transition out of his role of CFO following the Company's Q4 earnings report to pursue other opportunities. Foot Locker is initiating a comprehensive search, with the assistance of a leading executive recruiting firm, to identify his successor. Rosalind Reeves, Vice President, Talent, Diversity and Organization Capability, has been promoted to Executive Vice President and Chief Human Resources Officer, effective December 1. Reeves brings to the role more than 25 years of experience in human resources and deep expertise in talent acquisition and talent management; Diversity, Equity, and Inclusion programs; employee engagement, learning and development; and benefits. Reeves succeeds Elizabeth Norberg, who will step down as Chief Human Resources Officer, effective December 1, and will remain with the Company for a transition period. Robert Higginbotham, Vice President, Investor Relations, has been promoted to Senior Vice President, Investor Relations and Financial Planning and Analysis, effective December 1. In his expanded role, Higginbotham will have direct responsibility for the Financial Planning and Analysis team, in addition to Investor Relations.

16:07 EST Synopsys appoints Shelagh Glaser as CFO - Synopsys announced that it has appointed Shelagh Glaser as CFO, effective December 2. Previous CFO Trac Pham, who announced his planned retirement in December 2021, will remain with the company through December 2022 to ensure an orderly transition. Glaser joins Synopsys from Zendesk, a software-as-a-service CRM company, where she served as chief financial officer for the last two years. Prior to its acquisition by a consortium led by Hellman & Friedman and Permira, she led global finance, which includes finance and strategy, accounting, corporate reporting and forecasting, as well as procurement, real estate and investor relations. Glaser serves on the board of PubMatic, a leader in the digital advertising supply chain, and is a member of the audit committee. Prior to joining Zendesk, Glaser grew her career at Intel (INTC) over 29 years, most recently as a corporate vice president of Intel's two largest business units. She served as CFO and COO for the Data Platform Group and the Client Computing Group. She holds an MBA from Carnegie Mellon University and a bachelor's degree in economics from the University of Michigan.

16:05 EST X4 Pharmaceuticals announces 4WHIM trial meets primary endpoint - X4 Pharmaceuticals announced top-line results from the global, pivotal Phase 3 clinical trial, or 4WHIM, of its lead investigational therapy, mavorixafor, a novel CXCR4 antagonist, in people with WHIM syndrome. 4WHIM met its primary endpoint, with mavorixafor achieving clinical and statistical superiority over placebo when measuring TATANC, or the length of time that participants' absolute neutrophil counts, or ANC, remained above a clinically meaningful threshold of 500 cells per microliter over 24-hour periods at four time points throughout the 52-week trial. Mean TATANC, was 15.04 hours in the treatment group versus 2.75 hours in the placebo group. 4WHIM also met a key secondary endpoint, with mavorixafor achieving clinical and statistical superiority over placebo when measuring TATALC, or the length of time that participants' absolute lymphocyte counts, or ALC, remained above a clinically meaningful threshold of 1,000 cells per microliter, over 24-hour periods at four time points throughout the 52-week trial. Mean TATALC was 15.80 hours in the treatment group versus 4.55 hours in the placebo group. Increases in both TATANC and TATALC were maintained versus placebo and baseline across 52 weeks, demonstrating durability of treatment effect during the trial. Mavorixafor was generally well tolerated in the trial, with no treatment-related serious adverse events reported and no discontinuations for safety events. Following completion of the placebo-controlled portion of the trial, more than 90% of the eligible participants opted to receive treatment with mavorixafor in the open-label trial extension. Additional data review and analysis of the secondary and exploratory endpoints of the 4WHIM trial are ongoing, with plans to present detailed results at a future medical meeting.

16:05 EST Inter&Co joins Amazon's Payment Service Provider Program - Inter&Co (INTR), a Brazilian Super App offering a services in banking, investments, credit, insurance, shopping and remittance-related services, announced that it has joined Amazon's Payment Service Provider, or PSP, Program. The program requires any seller who uses PSP for revenue collecting to work with an Amazon-approved provider. Inter's Brazilian clients - who are sellers with Amazon US -will now be able to receive and send payments directly to their Inter accounts. Amazon launched the program in March 2021 as part of its ongoing efforts to be the most dependable e-commerce marketplace for customers and retailers around the world.

16:03 EST Workday announces $500M share repurchase program - Workday announced that its Board of Directors approved a new share repurchase program with authorization to purchase up to $500M of shares of its Class A common stock.

15:49 EST Roche's Genentech voluntarily withdraws U.S. indication of Tecentriq - Genentech, a member of the Roche Group, announced yesterday that the company is voluntarily withdrawing the U.S. indication of Tecentriq for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 or are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Genentech made this decision following consultation with the U.S. Food and Drug Administration, in accordance with the requirements of the FDA's Accelerated Approval Program. The Phase III IMvigor130 trial was designed to evaluate Tecentriq plus platinum-based chemotherapy for the first-line treatment of people with previously untreated advanced bladder cancer. IMvigor130 was the designated postmarketing requirement to convert the accelerated approval to regular approval, and it did not meet the co-primary endpoint of overall survival for Tecentriq plus chemotherapy compared with chemotherapy alone. These data will be presented at an upcoming medical meeting.

15:30 EST Avangrid 'pleased' with Maine Supreme Court ruling on NECEC - The Maine Supreme Judicial Court ruled that the State of Maine acted within its constitutional authority in granting a lease to NECEC developers for the New England Clean Energy Connect transmission line project, announced Avangrid. Scott Mahoney, Senior Vice President - General Counsel at Avangrid, stated: "Today's ruling by the Law Court is yet another step in the right direction for Maine's renewable energy future. The serious need for the NECEC project to reduce our reliance on fossil fuels, combat climate change, and lower regional energy prices remains unchanged. For the past three years, despite opposition funding by fossil fuel interests, every regulatory body at the local, state, and federal level has thoroughly reviewed the New England Clean Energy Connect and all agree the NECEC is beneficial for Mainers. We are pleased with today's ruling and look forward to determining our next steps for this critical project."

14:13 EST Sorrento reports safety and pharmacokinetic data from Phase I study of STI-1558 - Sorrento Therapeutics released Topline safety and pharmacokinetic data from the Phase I single ascending dose/multiple ascending dose study of STI-1558 conducted in 58 healthy volunteers in Australia. "Topline safety and PK data from the SAD and MAD portions of the study are now available. Overall, there were no changes in vital signs, physical examinations, or ECGs resulting from study participation. STI-1558 was well-tolerated at the doses studied, with most subjects reporting no AEs. There was no dose limiting toxicity and no severe or serious adverse events, premature discontinuation of STI-1558 due to an AE, or deaths. Most AEs were mild and unrelated. A total of 11 subjects reported an AE in the SAD part of the study, with 3 AEs of headache deemed related to STI-1558 - one moderate severity in the 600 mg cohort and two mild cases in the 1200 mg cohort - possibly due to restricted caffeine intake. In the MAD part of the study, 13 subjects reported AEs, with only two subjects experiencing related events of mild or moderate liver enzyme elevation without bilirubin elevation in the highest dose cohort, 800 mg BID, which is 33% higher for 50% longer than the planned treatment regimen for Phase II, 600 mg BID for 5 days. The liver enzyme elevations occurred late in study treatment and resolved without the need for any treatment," the company reported. "The unblinded safety and PK data in the Australia trial and the preliminary efficacy data from the China trial in participants infected with SARS-CoV-2 are very encouraging, and we are engaging with regulatory agencies on global Phase II/III trial design in order to initiate the STI-1558 Phase II/III trials in Mexico, the US and China as soon as possible," stated Henry Ji, Ph.D., President and CEO of Sorrento.

13:59 EST Suncor says Terra Nova will start production during the 1Q23 - Terra Nova will start production during the 1st quarter of 2023; the expected timing of Suncor's acquisition of an incremental 21.3% share of Fort Hills and the UK divestiture in the E&P segment; and statements regarding Suncor's multi year plan to deliver marked improvements in safety, reliability and operational performance. In addition, all other statements and information about Suncor's strategy for growth, expected and future expenditures or investment decisions, commodity prices, costs, schedules, production volumes, operating and financial results and the expected impact of future commitments are forward-looking statements. Some of the forward-looking statements. Reference Link

13:39 EST Rail union BMWED 'disappointed' in Biden proposal not including 'paid sick days' - "The Brotherhood of Maintenance of Way Employees Division of the International Brotherhood of Teamsters is deeply disappointed by and disagrees with United States President Joseph R. Biden's statement, calling upon Congress to pass legislation that would adopt tentative agreements between Railroad Workers and railroads that do not include paid sick days for Railroad Workers. It is not enough to "share workers' concerns." A call to Congress to act immediately to pass legislation that adopts tentative agreements that exclude paid sick leave ignores the Railroad Workers' concerns. It both denies Railroad Workers their right to strike while also denying them of the benefit they would likely otherwise obtain if they were not denied their right to strike. Additionally, passing legislation to adopt tentative agreements that exclude paid sick leave for Railroad Workers will not address rail service issues. Rather, it will worsen supply chain issues and further sicken, infuriate, and disenfranchise Railroad Workers as they continue shouldering the burdens of the railroads' mismanagement. Indeed, the big corporations, the monopolies that control America - the robber baron railroads - have again profiteered from the problem they created and shifted the consequences of it onto the Railroad Workers, the customers, and the general public. This cannot continue. There must be a change. BMWED calls upon President Biden and any member of Congress that truly supports the Working Class to act swiftly by passing any sort of reforms and regulations that will provide paid sick leave for all Railroad Workers. BMWED will continue fighting for paid sick days for every Railroad Worker because it is unreasonable and unjust to insist a person perform critical work when they are unwell," said the union in a blog post. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

13:34 EST AstraZeneca announces sale of West Chester, Ohio manufacturing site - AstraZeneca announces the sale of its West Chester site in Ohio, U.S., to National Resilience, a "technology-focused manufacturing company dedicated to broadening access to complex medicines." AstraZeneca expects to complete the sale in the first quarter of 2023, with a phased transition of services. Andrew Wirths, Senior Vice President, Americas Supply Region, AstraZeneca, said: "As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimising our manufacturing footprint to meet the evolving needs of our pipeline and portfolio. The transfer of our West Chester site to Resilience will enable the continued supply of AstraZeneca medicines to patients, as well as the continued employment for more than 500 people working at the West Chester site. I'm encouraged by Resilience's plans to transform the site into their drug product centre of excellence."

13:28 EST Amazon announces AWS Clean Rooms - At AWS re:Invent, Amazon Web Services, an Amazon.com company, announced AWS Clean Rooms, which it calls "a new analytics service that helps companies across industries easily and securely analyze and collaborate on their combined datasets-without sharing or revealing underlying data." The company stated: "With AWS Clean Rooms, customers can create a secure data clean room in minutes and collaborate with any other company in the AWS Cloud to generate unique insights about advertising campaigns, investment decisions, clinical research, and more. AWS Clean Rooms provides a broad set of built-in data access controls that protect sensitive data, including query controls, query output restrictions, query logging, and cryptographic computing tools."

13:23 EST Teck Resources appoints Crystal Prystai as SVP, CFO - Teck Resources announced the appointment of Crystal Prystai as Senior Vice President and CFO. Ms. Prystai succeeds Jonathan Price, who was appointed CEO earlier this year. Prystai joined Teck in 2008 and has held progressively more senior roles, most recently, Interim CFO.

12:56 EST Empowerment & Inclusion Capital I Corp trading halted, news pending

12:48 EST Shopify reports Black Friday Cyber Monday weekend sales up 19% y/y - Shopify announced earlier a record-setting Black Friday Cyber Monday weekend, with sales of $7.5B from independent businesses worldwide. That's a 19% increase in sales from the $6.3B during Shopify's Black Friday Cyber Monday weekend in 2021, or 21% on a constant currency basis, Shopify said in a statement. More than 52 million consumers globally purchased from brands powered by Shopify this year, an 18% increase from 2021, it added. "This year, Black Friday Cyber Monday showed us once again that consumers are voting with their wallets to support the independent brands they love," said Harley Finkelstein, President of Shopify. "We saw record level shopping happening across all channels this weekend, proving businesses that meet their customers where they are, whether that's online or in-person, will earn their loyalty in return." Reference Link

12:36 EST AWS announces Amazon DataZone - At AWS re:Invent, Amazon Web Services, an Amazon.com company, announced Amazon DataZone, which it calls "a new data management service that makes it faster and easier for customers to catalog, discover, share, and govern data stored across AWS, on-premises, and third-party sources." AWS stated: "With Amazon DataZone, administrators and data stewards who oversee an organization's data assets can manage and govern access to data using fine-grained controls to ensure it is accessed with the right level of privileges and in the right context. Amazon DataZone makes it easy for engineers, data scientists, product managers, analysts, and business users to access data throughout an organization so they can discover, use, and collaborate with data to derive insights."

12:32 EST PropTech Investment II Corp trading halted, volatility trading pause

12:00 EST Allego falls -9.0% - Allego is down -9.0%, or -33c to $3.38.

12:00 EST Enfusion falls -16.1% - Enfusion is down -16.1%, or -$1.98 to $10.32.

12:00 EST Geo Group rises 10.4% - Geo Group is up 10.4%, or $1.06 to $11.29.

11:52 EST Orbital Infrastructure Group's IMMCO acquires office space in India - Orbital Infrastructure Group announced that IMMCO, Inc, a subsidiary of OIG's Telecom Platform, GTS, has achieved record sales through Q3. IMMCO, based in Canton, GA, with offices in India, Europe and Australia, also reported the acquisition of new office space and the hiring of 60 new employees in Kochi, India, increasing their technical engineering staff to more than 800. Through September 30, 2022, GTS sales exceeded the same period of 2021 by 119% - setting an all-time company record for the first three quarters of this year. A significant catalyst to this growth has been the increasing demand for IMMCO's broadband engineering and design services. To facilitate this revenue increase and further capacity, IMMCO is undertaking its fourth office expansion in 2022, opening a new 9,500 sf facility in January of 2023. The recent addition of 60 new employees takes IMMCO's staff to over 800, and the new office space will enable staffing expansion to around 1,200.

11:08 EST Alector presents results from Phase 1 study of AL101 - Alector reported safety and biomarker data from a first-in-human Phase 1 healthy volunteer study of AL101, a human monoclonal antibody that blocks the sortilin receptor to increase progranulin levels. The data will be presented today during a poster session at the 15th Clinical Trials on Alzheimer's Disease conference held in San Francisco from November 29-December 2, 2022. AL101 is being developed for the potential treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, under Alector's collaboration with GSK. In a randomized, double-blind, placebo-controlled Phase 1 study in 88 heathy volunteers who received either single or multiple doses of AL101 administered intravenously or subcutaneously, AL101 was generally well tolerated and elevated PGRN levels in the cerebrospinal fluid. The study results that will be presented from the multiple-dose cohorts demonstrated that the product candidate's pharmacokinetic and pharmacodynamic profile supports development in multiple dosing schedules for chronic neurodegenerative conditions, such as AD and PD The data that will be presented at CTAD 2022 from the multiple-dose cohorts of the Phase 1 study build upon previous data reported at CTAD 2021 from the single-dose cohorts, which demonstrated that AL101 was well tolerated and increased PGRN levels in plasma and CSF in a dose-dependent manner. In the two MD cohorts, 27 healthy volunteers received either AL101 30 mg/kg IV every four weeks for a total of four doses or AL101 300 mg SC every two weeks for a total of seven doses. Three volunteers received MD IV placebo. Key highlights from the study include the following: AL101 was found to be generally well tolerated following MD IV and SC administrations. Consistent with previously presented data following single doses, AL101 was measurable in the CSF following multiple IV and SC doses. MD administration of AL101 increased plasma and CSF PGRN levels, with a higher elevation observed in the AL101 30 mg/kg MD IV group than in the AL101 300 mg MD SC group. Multiple IV doses of AL101 at 30 mg/kg increased and maintained the levels of PGRN at approximately 160% to 200% above baseline in plasma and approximately 80% above baseline in the CSF. The PK and PD profile of AL101 following single and multiple IV doses support future development in chronic neurodegenerative conditions such as AD and PD.

11:02 EST uniQure reports on progress made in developing AMT-260 - uniQure hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy, or rTLE, and other focal epilepsies in an event that featured a presentation from rTLE clinical expert Ellen Bubrick, MD, associate chair of Neurology at Harvard Medical School and director of the Epilepsy Surgery Program at Brigham and Women's Hospital in Boston, MA. "The presentation highlighted preclinical data that supports the safety and tolerability of AMT-260 and plans for its clinical development, as well as uniQure's miQURE and linQURE technology platforms that allow the Company to use miRNAs to safely reduce the expression of genes in the brain. The company also highlighted its progress in developing a commercial-scale AAV manufacturing platform," the company stated. "One week after the landmark FDA approval of the uniQure-developed world's first gene therapy for hemophilia B, we are pleased to share the progress that we have made in developing AMT-260, a first-in-class gene therapy for temporal lobe epilepsy. Today's event presented the preclinical data and the innovative technologies that we hope will allow us to develop AMT-260 and other gene therapies that can locally regulate neuronal activity for diseases of the central nervous system. We look forward to continuing to work toward submitting an investigational new drug application for AMT-260 and advancing it into the clinic in 2023," stated Ricardo Dolmetsch, Ph.D., president of research & development at uniQure.

10:43 EST Express up 14c to $1.44 after announcing refinancing transactions - Express last night announced two transactions in support of "a comprehensive plan to refinance its capital structure and expand its liquidity access while concurrently reducing interest rate exposure and providing flexibility to pay down its outstanding term debt balance," including increasing the maximum revolver amount by $40M to $290M by amending its current $250M Senior Secured Asset-Based Revolving Credit Facility and refinancing and reducing Express' fixed debt exposure by amending its current $140M Senior Secured Asset-Based Term Loan Credit Facility, including refinancing its $90M First-In-Last-Out Term Loan and terminating its $50M Delayed Draw Term Loan, of which $43M was previously paid down. "We are pleased to complete these refinancing transactions, which bolster our liquidity access, strengthen our balance sheet, reduce our interest rate exposure and improve our capital structure," said Jason Judd, Chief Financial Officer at Express. "We will continue working to reduce debt exposure in 2023. Under the terms of the Amended Term Loan Facility, Express can use proceeds from the $52 million CARES Act receivable to pay down outstanding term debt. With enhanced financial flexibility, we believe we are well-positioned to continue executing our EXPRESSway Forward strategy and pursuing growth opportunities." In early trading, shares of Express are up 14c, or 11%, to $1.44 following the refinancing news.

10:22 EST Digital Brands Group Inc trading resumes

10:03 EST Gray Television extends network affiliations for all ABC stations - Gray Television (GTN) announced that it has entered into agreements with Disney (DIS) that extend and renew the network affiliations for all of Gray's ABC affiliated television stations across 25 markets through December 31, 2024. "We are pleased to announce the further extension of our decades-long relationship with Disney for ABC station affiliations," said Gray's President and Co-CEO, Pat LaPlatney. "These agreements recognize our ABC affiliates' commitment to public service and will help them continue to serve their communities."

10:02 EST Knightscope sees revenue run rate $12M-$14M in next 12 months - Knightscope announced its anticipated revenue growth for the next twelve months and will be broadcasting the first video episode in a series titled "Rise of the Robots" today across its social media platforms. "We'll be filing the 8-K for the combined entity at the end of the year," said William Santana Li, Knightscope's chairman and CEO. "We expect that the two units together will likely be running at a revenue run rate in the range of $12M - $14M delivering on the accelerated growth by a significant margin versus the $3.4M from 2021. The Rise of the Robots is happening."

10:00 EST ZipRecruiter falls -7.1% - ZipRecruiter is down -7.1%, or -$1.22 to $15.95.

10:00 EST Nordic American Tankers rises 9.3% - Nordic American Tankers is up 9.3%, or 31c to $3.64.

10:00 EST Full Truck Alliance rises 9.9% - Full Truck Alliance is up 9.9%, or 66c to $7.29.

09:52 EST First Reliance Bank COO Robert Dozier departs - First Reliance Bancshares announced a change in the Bank's management team. Robert Dozier, Senior Executive Vice-President and COO of First Reliance Bank, announced his departure from the organization to become the CEO of a non-bank financial services company, effective December 31, 2022. The existing management team will perform duties previously performed by the COO, and the Bank does not anticipate hiring a new COO at this time.

09:49 EST Nestle to explore strategic options for peanut allergy treatment - Nestle announced that it has decided to explore strategic options for Palforzia, the peanut allergy treatment, "following slower than expected adoption by patients and healthcare professionals." The review is expected to be completed in the first half of 2023. Going forward, Nestle Health Science "will sharpen its focus" on Consumer Care and Medical Nutrition.

09:47 EST Generac falls -4.6% - Generac is down -4.6%, or -$4.71 to $97.34.

09:47 EST Enfusion falls -6.9% - Enfusion is down -6.9%, or -84c to $11.46.

09:47 EST Miniso rises 8.5% - Miniso is up 8.5%, or 83c to $10.59.

09:36 EST Cognizant to acquire consultancy AustinCSI; terms not disclosed - Cognizant announced it has entered into an agreement to acquire AustinCSI, a digital transformation consultancy specializing in enterprise cloud and data analytics advisory services. The transaction is expected to close in the fourth quarter of 2022, subject to satisfaction of closing conditions. Financial details were not disclosed. "Client demand for end-to-end digital strategy and industry-specific solutions continues to accelerate," said Michael Valocchi, Senior Vice President, Head of Cognizant Consulting and Americas Strategy. "AustinCSI has built a stellar reputation by improving business outcomes for some of the world's most recognizable brands, particularly in the telecommunications, media, technology and automotive sectors, markets where Cognizant is also strong. We look forward to welcoming AustinCSI's talented experts to our team and further enriching the value we're providing to our clients as they embrace cloud, AI, data analytics, and other advancing technologies."

09:32 EST RGC Resources raises quarterly dividend 1.3% to 19.75c per share - The Board of Directors of RGC Resources, at its meeting on November 28, 2022, declared a quarterly dividend of 19.75c per share on the Company's common stock. The indicated annual dividend is 79c per share, a $0.01 or 1.3% per share increase over the prior annual level. The Company has now increased the annual dividend 19 consecutive years. The dividend will be paid on February 1, 2023 to shareholders of record on January 18, 2023. This is the Company's 315th consecutive quarterly cash dividend.

09:21 EST Reunion Gold announces appointment of Howes to board of directors - Reunion Gold announces that Richard Howes has been appointed to the board of directors of the Company. As announced on November 21, 2022, Howes will be appointed President and Chief Executive Officer of the Company effective January 1, 2023. The Company has granted 2,000,000 stock options to Howes. The Options are exercisable at a price of $0.44, will vest in three instalments commencing on January 1, 2023, and have a term of five years. The Options were granted pursuant to the Company's incentive stock option plan and are subject to regulatory approval.

09:19 EST Varonis launches HackerOne vulnerability disclosure program - Varonis Systems announced the launch of its public vulnerability disclosure program via HackerOne. The Varonis Vulnerability Disclosure Program enables the entire HackerOne community to report potential security issues related to Varonis' corporate and cloud environments, including Varonis SaaS products. Varonis CISO Guy Shamilov said, "Varonis has had tremendous success with our private bug disclosure program, and the logical next step for us is to partner with HackerOne, the undisputed leader in vulnerability coordination and bug bounty management. Varonis has always remained committed to providing the best security for our platforms," continued Shamilov. "With the public launch of our Varonis SaaS offering, we are continuing our tremendous investment in product security. Moving forward, our HackerOne VDP will make it possible for threat researchers to report issues easily and safely, which will help keep our products, and in turn, our customers, more secure."

09:18 EST SeaStar Medical appoints Barnett as chairman of board of directors - SeaStar Medical announced the appointment of Rick Barnett as Chairman of the Company's Board of Directors. Barnett has served on the SeaStar Medical Board as a Director since January 2021, and currently serves as Chair of the Compensation Committee and a member of the Audit Committee. Barnett has extensive experience in strategic transactions and financial analysis for healthcare and medical device companies. Barnett joined SeaStar Medical's Board of Directors after serving as President, Chief Executive Officer and Board Member of Satellite Healthcare for seven years.

09:17 EST Tetra Tech awarded $72.5M USAID contract - Tetra Tech announced that the U.S. Agency for International Development, or USAID, has awarded the company a $72.5M, single-award, five-year contract to increase access to financing for climate-resilient water and sanitation services. Globally, hundreds of millions of people lack access to basic drinking water, and more than a billion people lack access to basic sanitation services. Through the USAID Water, Sanitation, and Hygiene Finance 2 activity, Tetra Tech will work with government and financial institutions, development partners, service providers, and local stakeholders to mobilize the financing required to expand WASH services. Tetra Tech water resources and infrastructure experts will support water service providers to improve climate resilience and strengthen their business models through data-driven decision-making.

09:16 EST Motorsport Games announces entry list for 500 Miles of Sebring - The entry list for the 500 Miles of Sebring, fourth round of the 2022-23 Le Mans Virtual Series - the global, elite endurance esports series and a joint venture between Motorsport Games and the Automobile Club de l'Ouest has been revealed. The race will take place on Saturday, December 3 and is the final round before the legendary 24 Hours of Le Mans Virtual in January. The list features standout names from the real world of motorsport, including Team Redline's two-time Formula One World Champion Max Verstappen, former F1 and current INDYCAR star Romain Grosjean and W Series and sportscar racing's Beitske Visser for Mahle Racing Team, plus many more representing the most prestigious automotive manufacturers in the world. They are joined by elite esports squads from around the globe, and gaming stars such as Jeffrey Rietveld (Team Redline), Josh Rogers and Tommy Ostgaard from Porsche Coanda Esports, and Lorenzo Arisi from Ferrari's SIM Maranello entry.

09:15 EST BAE Systems expands network of modeling, simulations to include Microsoft - BAE Systems (BAESY) is expanding the network of companies in its modeling and simulations ecosystem to include Microsoft (MSFT). With this addition, BAE Systems' Pioneer wargaming platform will use Microsoft's Azure cloud computing enabled services to deliver more realism in the platform's high fidelity simulations providing customers increased confidence in decision making.

09:14 EST Fat Brands announces opening of first tri-branded location - FAT Brands announces the opening of its first tri-branded location to date, a Fatburger, Buffalo's Express and Hot Dog on a Stick. Situated in the Los Angeles neighborhood of Valley Village, the restaurant boasts a classic all-American menu of custom-built burgers, Fat and Skinny Fries, fresh, all-natural chicken wings and savory hot dog on a stick and cheese on a stick products. The Fatburger, Buffalo's Express and Hot Dog on a Stick tri-branded restaurant is located at 4806 Laurel Canyon Boulevard, Valley Village, CA 91607 and is open daily from 10 a.m. to 11 p.m.

09:13 EST Mayfair Gold announces private placement financings - Mayfair Gold announced it has arranged a non-brokered private placement financing of up to 2,600,000 common shares at a price of $1.15 per share for aggregate gross proceeds of up to $3.0M, and a concurrent non-brokered private placement of up to 3,000,000 common shares on a flow-through basis at a price per FT Share of $1.66, which represents a premium of 32% over the closing price of Mayfair Gold common shares on the TSX.V on November 28, 2022, for aggregate gross proceeds of up to $5M. The net proceeds of the Offering will be used to further Mayfair's successful exploration program in addition to environmental, metallurgical and engineering studies at the Fenn-Gib gold project in the Timmins region of Ontario. A portion of the net proceeds of the Shares issued under the Offering will be reserved for working capital. Finders' fees may be payable on a portion of the Offering. All proceeds from the sale of the FT Shares will be used for expenditures which qualify as Canadian Exploration Expenses within the meaning of the Income Tax Act. The Company will renounce such CEE expenditures with an effective date of no later than December 31, 2022. The shares issued under the Offering will be subject to a four-month hold period. The Offering of FT Shares is expected to close on or before December 20, 2022, and the Offering of Shares is expected to close on or about December 31, 2022. The Offering is subject to customary closing conditions, including approval from the TSX.V.

09:11 EST Consolidated Communications appoints Fred Graffam as CFO - Consolidated Communications announced the appointment of Fred Graffam as executive vice president and chief financial officer effective Dec. 1. After a distinguished career within the telecommunications industry, Steve Childers will transition from chief financial officer to an advisory role until Dec. 31 to ensure a smooth transition.

09:08 EST AvePoint appoints Briggs to VP of U.S. Public Sector - AvePoint (AVPT) announced the appointment of Kevin Briggs to Vice President of U.S. Public Sector supporting customers in education, federal, state and local governments. Briggs joins amid strong revenue and SaaS growth, as reported in Q3 earnings, and will accelerate support for U.S. public sector organizations who face complex challenges in the cloud. Briggs brings two decades of experience in the federal government space to AvePoint. He previously held leadership positions at Microsoft (MSFT) and Qualtrics (XM)

09:08 EST Chemours 'tracking slightly below' low end of FY22 adjusted EBITDA, FCF guidance - Chemours said it is currently tracking slightly below the low end of its FY22 adjusted EBITDA guidance of $1.4B-$1.45B and free cash flow guidance of greater than $575M. In investor presentation slides, Chemours said TiO2 market demand has weakened in Q4 and it is taking strategic cost actions in order to better position the business for 2023 and beyond. Chemours shares are down about 6% in pre-market trading.

09:06 EST CareCloud selected by Cornerstone Healthcare Group for professional billing - CareCloud announced Cornerstone Specialty Hospitals West Monroe has selected CareCloud to handle its revenue cycle management services to strengthen their capabilities and drive better financial outcomes. Cornerstone Healthcare Group operates 15 hospitals throughout the U.S., including the West Monroe, Louisiana, location, which specializes in acute care for patients with complex medical needs. CareCloud's RCM services will integrate with Cornerstone's electronic health record vendor to support the West Monroe location's professional billing.

09:03 EST Openly powers customer experience with Verisk data - Openly is delivering a modern, simplified customer experience powered by advanced technology and data from Verisk. With Verisk's LightSpeed for Homeowners platform, Openly is amplifying their data-forward strategy that optimizes the ordering of rating and underwriting information in real time and helps independent agents deliver innovative products and service to homeowners. Openly is leveraging LightSpeed to support its efforts to enhance the quoting process for independent agents, refine underlying models and continue its profitable growth into new states.

08:59 EST Hyatt to acquire Dream Hotel Group lifestyle hotel brand, platform for $125M - Hyatt and Dream Hotel Group announced an agreement for a Hyatt affiliate to acquire Dream Hotel Group's lifestyle hotel brand and management platform including the Dream Hotels, The Chatwal Hotels and Unscripted Hotels brands, with properties in some of the world's most prominent hotel markets across the Americas, Europe and Asia. This asset-light acquisition will include a portfolio of 12 managed or franchised lifestyle hotels, with another 24 signed long-term management agreements for hotels expected to open in the future. Upon closing, this expansion will add over 1,700 rooms to Hyatt's lifestyle portfolio and increase Hyatt's room count in New York City by more than 30%. This acquisition continues Hyatt's asset-light growth strategy following its transactions to acquire Two Roads Hospitality in 2018 and Apple Leisure Group in 2021 - and, most recently, Hyatt's collaboration agreement with German Lindner Hotels AG, to further grow Hyatt's brand footprint in Europe. Upon closing, Hyatt will pay a base purchase price of $125M, with up to an additional $175M over the next six years as properties come into the pipeline and open. Stabilized management fees associated with the base purchase price of $125M are anticipated to be approximately $12M and, to the extent the contingent purchase price of $175 million is paid, additional stabilized management fees are anticipated to be up to approximately $27M. The total base purchase price plus the contingent purchase price represents an attractive acquisition multiple in the high-single digits on projected stabilized earnings.

08:52 EST Greenlane enters strategic partnership with Wild Green Canada - Greenlane announced its strategic partnership with Wild Green Canada to streamline business-to-business processes and increase Greenlane's product reach into Canada. Through its B2B website, outside salesforce, and experienced leadership team, Greenlane's partnership with Wild Green Canada will expand Greenlane's product reach to a wider base of retail stores in Canada, ultimately increasing visibility and Greenlane's growth. Wild Green Canada has been involved in the Canadian tobacco industry for over 45 years. Wild Green Canada intends to leverage this experience to expand their portfolio to the legal cannabis market.

08:51 EST Novavax's COVID-19 vaccine issued Emergency Use update by WHO - Novavax announced that the World Health Organization - WHO - has issued an updated Emergency Use Listing for Nuvaxovid COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.

08:47 EST Greenlane enters partnership with Wild Green Canada - Greenlane Holdings announced its strategic partnership with Wild Green Canada to streamline business-to-business processes and increase Greenlane's product reach into Canada. The partnership with Wild Green Canada aligns with Greenlane's focus on accelerating growth and a path towards profitability. Through its B2B website, outside salesforce, and experienced leadership team, Greenlane's partnership with Wild Green Canada will expand Greenlane's product reach to a wider base of retail stores in Canada, ultimately increasing visibility and Greenlane's growth. Wild Green Canada has been involved in the Canadian tobacco industry for over 45 years. Wild Green Canada intends to leverage this experience to expand their portfolio to the legal cannabis market.

08:42 EST Oramed's ORMD-0801 meets primary endpoint in peer-reviewed publication - Oramed announced that Diabetes, Obesity, and Metabolism, has published an original article which presents the results of a 12-week multicenter, randomized, placebo-controlled trial assessing the safety and efficacy of multiple active doses of Oramed's lead drug candidate ORMD-0801 in patients with uncontrolled Type 2 Diabetes on chronic background therapy with Metformin or combination oral therapy. The trial met the primary endpoint of statistically significant reductions of HbA1c from baseline to Week 12. In addition, the treatment doses were safe, well tolerated and not associated with weight gain or hypoglycemia.

08:38 EST Cemtrex completes divestiture of non-core assets - Cemtrex announced that the Company has undertaken a transformative restructuring in which it has divested its Smartdesk and VR subsidiaries in order to focus exclusively on its Vicon Industries and Advanced Industrial Services businesses. The restructuring is the culmination of Cemtrex's previously announced strategic shift towards prioritizing its core businesses. "Surveillance industry trends are rapidly evolving toward Video Surveillance as a Service (VSaaS) as end-users seek a reliable source of video surveillance and access control technologies fit for today's highly dynamic environment," said Saagar Govil, Chairman and CEO of Cemtrex. "We continue to see escalating demand from major customers for Vicon's expanding line of Valerus products and software services, with Allied Market Research predicting the global VSaaS and video surveillance market will reach over $83 billion by 2030 with a CAGR of 10.9% between 2021 and 2030." As part of the strategic restructuring, on November 22, 2022, Cemtrex completed a divestiture of its Smartdesk, CXR services, Cemtrex Labs, Virtual Driver Interactive and Bravo Strong assets and trade liabilities, allowing Cemtrex to focus on the Vicon and AIS businesses. The divestment of the subsidiaries was accomplished through a sale to existing management of Cemtrex, led by Saagar Govil. On November 22, 2022, the Company completed the disposition of assets and certain liabilities for the following consideration: Cemtrex XR - $895,000 comprised of: $75,000 in cash payable at Closing; 5% royalty of all revenues on the Business to be paid 90 days after the end of each calendar year for the next three years; and should the total sum of royalties due be less than $820,000 at the end of the three-year period. Cemtrex Advanced Technologies - $10,000 in cash payable at Closing; 5% royalty of all revenues on the Business to be paid 90 days after the end of each calendar year for the next 5 years; and $1,600,000 in "SAFE" at any subsequent fundraising or exit above $5M with a $10M cap.

08:37 EST Grom Social engage MZ Group to lead strategic investor relations program - Grom Social Enterprises has engaged international investor relations specialists MZ Group to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Grom management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight Grom's portfolio of offerings that feature safe social media for children under 13 and a catalog of intellectual properties designed to serve the entertainment needs of today's kids and families through films, TV series, publishing and consumer products, and international distribution. "Our commitment to protecting kids in the modern digital age is fundamental to our operating strategy across our portfolio of subsidiaries," said Darren Marks, Chairman and CEO of Grom Social Enterprises, Inc. "Our animation studio has built a strong reputation in the entertainment industry, and by managing it in tandem with our original content subsidiary, Grom is able to deliver our award-winning content to top tier programmers around the globe. We have assembled a team of leaders that have been instrumental in growing blue-chip networks such as Nickelodeon, and by leveraging their industry knowledge and relationships, we are well positioned to achieve leadership in our niche market"

08:35 EST Host Hotels appoints Mari Sifo as EVP, Chief Human Resources Officer - Host Hotels & Resorts announced the appointment of Mari Sifo as executive vice president, EVP, and chief human resources officer, effective November 28, 2022. She succeeds Joanne Hamilton who previously announced her retirement. Sifo joins the Company with more than 20 years of strategic human resources and business leadership experience at both private and public companies. In her new role, she will serve as a key member of the Company's executive management team and will oversee all aspects of human resources. She will also serve on the Corporate Responsibility Executive Steering Committee. Most recently, Sifo served as chief human resources and communications officer at SWM International, a global manufacturer of specialty materials.

08:34 EST Apollo Global appoints Wooden as Partner, Chief Public Pension Strategist - Apollo Global Management announced the appointment of Shawn Wooden as Partner and Chief Public Pension Strategist for Apollo's Institutional Client & Product Solutions group, ICPS. In this newly created role, Wooden will be responsible for deepening Apollo's relationships with public pension plans, expanding its product offerings to further meet the needs of pension plans, and providing thought leadership in this rapidly evolving market. In January 2023, Wooden will retire as the 83rd State Treasurer of Connecticut, a role he assumed in January of 2019.

08:33 EST Upexi's toy brand Tytan Tiles to launch in Walmart retail stores in January - Upexi's (UPXI) children's toy brand Tytan Tiles will expand its retail presence nationally through 2,000 Walmart (WMT) stores, with products to hit shelves in January 2023. Tytan is an eco-conscious toy company that has grown 100% over the past two years. Tytan will be featured in the Walmart.com 2022 CYBER Monday promotions.

08:32 EST Churchill Downs, DraftKings enter agreement to develop, launch DK HORSE - Churchill Downs (CHDN) and DraftKings (DKNG) announced a multi-year agreement that will bring pari-mutuel wagering on horse racing to DraftKings. CDI's subsidiary, TwinSpires, will provide advance deposit wagering technology to DraftKings. TwinSpires is the premier, market leading online horse racing wagering platform in the U.S. DraftKings will launch DK HORSE in the coming months, which will allow DraftKings' eligible customers to bet on horse racing using a standalone branded app. DK HORSE is expected to be available initially in 21 states, pending all necessary licensing and regulatory approvals, and is scheduled to launch ahead of the 149th running of the Kentucky Derby in May 2023. Under the agreement, CDI will provide DraftKings pari-mutuel wagering rights to horse racing content owned or controlled by CDI, including the Kentucky Oaks and Kentucky Derby. "We believe the depth and quality of our online offering through TwinSpires is unmatched in horse racing," said Bill Carstanjen, CEO of CDI. "We are excited to establish this relationship with DraftKings and to deliver a full end-to-end white label ADW solution that will introduce their significant base of sports betting customers to horse racing wagering."

08:27 EST Globant creates new unit for expansion into Asia-Pacific and Middle East region - Globant announced its expansion across Asia-Pacific and the Middle East with the creation of a new, fully dedicated regional unit called "New Markets." As part of this geographic expansion, Globant has made the following regional leadership appointments: Federico Pienovi, current Chief Business Officer for EMEA, will become CBO & General Manager for the New Markets Region; Fernando Matzkin, currently CBO for North America, will become Globant's CBO in Europe; Nicolas Kaplun, currently CBO for Latin America, will assume leadership over North America; Ignacio Iglesias, current Managing Director for Peru, Chile, and Ecuador, will take over as CBO for Latin America to keep expanding Globant's local presence.

08:25 EST Ethema expects to 'substantially grow' EBITDA in 2023 - Ethema Health Corporation recently filed the third quarter 2022 10-Q. The Company's ARIA subsidiary continued its growth and had a $712,839.00 EBITDA for the first nine months of the year. The Company's wholly owned subsidiary, PB Billing LLC, which started operating in May 2022, had an EBITDA of $34,579.00 for the first 9 months of the year. Companywide EBITDA for the first nine months of the year was $898,920.00. Detailed results are available in the SEC filings for the third quarter 10-Q. Additionally, on November 14, 2022, the Company received qualification from the SEC for its form 1A, which enables the company to raise new equity as outlined in the filing. The Company has begun due diligence on a potential acquisition expected to close in late January. Due to confidentiality agreements the Company is prohibited from disclosing the name of the potential target. The targeted acquisition cost is approximately $3.8 million. The Company is also set to close on the acquisition of the property leased by its ARIA subsidiary at the end of January 2023. Mr. Shawn Leon, Company CEO, reported, "We had set a goal at the beginning of the year for our ARIA subsidiary to produce an EBITDA of $1,000,000 for calendar 2022. It looks like we are on track to make that goal and are very proud of our many associates and team members for helping us get there. We have repeatedly indicated throughout the year that our dual goals were to grow the company and to manage and repay the debt we accumulated in previous years. In the next few months, we expect to make substantial progress on these goals with the new equity raise outlined in the filed form 1A. We expect to substantially grow the EBITDA in 2023 as growth will become our sole objective after repaying the debt."

08:22 EST Eyenovia announces $15M credit facility with Avenue Venture Debt Fund - Eyenovia announced that the company has entered into a $15 million credit facility with the Avenue Venture Opportunities Fund. The financing is intended to support manufacturing in anticipation of a MydCombi launch and clinical supply for ongoing programs. Per the terms of the agreement, Eyenovia received $10 million of gross proceeds at closing. The additional $5 million will be available, at the company's option, should MydCombi be approved for marketing in the U.S. by the Food and Drug Administration by August 2023. The Avenue facility replaces the company's Silicon Valley Bank facility, which was recently paid off. Eyenovia's current pro-forma unrestricted cash balance, including approximately $9.5 million of net proceeds from this facility, is approximately $25.5 million.

08:19 EST Immutep enters into second clinical trial agreement with Merck KGaA - Immutep (IMMP) announces it has signed a Clinical Trial Collaboration and Supply Agreement with Merck KGaA (MKKGY), Darmstadt, Germany and Pfizer for a new Phase I clinical study in patients with urothelial cancer, called INSIGHT-005. "We are very pleased to be deepening our collaboration with Merck KGaA, Darmstadt, Germany and Pfizer through this new study in patients with urothelial cancer, the sixth most common cancer in the US, who are in need of treatment options," said Immutep CEO, Marc Voigt. "INSIGHT-005 builds on the encouraging clinical efficacy and safety previously reported from the combination of efti and avelumab in various solid cancers, including deep and durable responses in patients with low or no PD-L1 expression and in indications that typically do not respond to immune checkpoint therapy." INSIGHT-005 will be an investigator-initiated explorative, open-label study evaluating the safety and efficacy of Immutep's lead product candidate, efti, in combination with avelumab in up to 30 patients with metastatic urothelial cancer. The study will take place in Germany. The first patient is expected to be enrolled and dosed in H1 of calendar year 2023, after completing the necessary ethics and regulatory steps. Under the Agreement, Immutep and Merck KGaA, Darmstadt, Germany will jointly fund the INSIGHT-005 study.

08:17 EST BioVie enrolls over 316 patients in Phase 3 trial of NE3107 - BioVie announced that more than 316 patients have enrolled in its Phase 3 trial, thereby achieving its trial enrollment target. Furthermore, the Company has opted to continue enrolling up to 400 patients without the pre-specified interim data analysis due to NE3107's safety in this study to date and a faster than expected pace of study enrollment. The NM101 trial is a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. The study has co-primary endpoints looking at cognition using the Alzheimer's Disease Assessment Scale-Cognitive Scale and function using the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The NM101 trial protocol specified enrolling at least 316 patients equally randomized to treatment and placebo arms. The protocol also pre-specified the potential for a review by the data safety monitoring board, in a manner that is blinded to the Company, when roughly 50% of the 316 enrolled patients have completed the study to determine if increasing enrollment of up to 400 patients might be desirable for the purpose of enhancing the probability of achieving statistical significance. The pace of enrollment increased dramatically in recent months, creating a situation where the Company finished enrolling all 316 patients before 50% of enrolled patients had completed the study. This decision to expand enrollment was informed by the following factors: The Company monitors blinded study data daily and has not observed any serious adverse events that appear to be attributed to the administered study drug. In addition, the safety review committee has met in September and in November to review current safety of the trial. This safety profile is consistent with what was seen in prior clinical trials showing no statistical difference in the AE rates for the treated vs. placebo groups; The recently released topline data from a Company-supported Phase 2 exploratory biomarker study showing that patients treated with NE3107 experienced improved cognition as measured by a modified ADAS-Cog12 score, reduced TNFalpha in a manner that's correlated to improvements in cognition, reduced CSF p-tau levels and the ratio of p-tau to Abeta42, and imaging findings suggestive of improved neuronal health. Despite the open-label nature of the exploratory study, the emerging data and correlations provide encouraging signs of what we may see in the upcoming Phase 3 data reveal; and The current pace of patient enrollment suggest that the additional 84 patients can be enrolled in approximately two months.

08:16 EST Alimera Sciences announces recent meeting findings, data from PALADIN study - Alimera Sciences announces findings from a recent meeting where data demonstrated a high level of agreement among retina specialists on the role of inflammation in the pathophysiology of diabetic retinopathy and diabetic macular edema, injection burden and patient adherence, and efficacy and safety of ILUVIEN 0.19 mg sustained release intravitreal implant. The company also announced analysis of data from the 36-month PALADIN study that found 0.19 mg Fluocinolone Acetonide provides long-term reduction of retinal thickness variability, which is correlated to improved visual outcomes and better disease control. Key Abstract Findings: A consensus was reached for seven of ten proposed statements. These included those related to: Chronic low-grade inflammation and the associated inflammatory cytokines are key drivers of DR/DME pathogenesis. Steroids have broad, non-specific anti-inflammatory properties, including the downregulation of VEGF production. Chronic low-grade inflammation, a result of poor glycemic control over time, can lead to neurodegenerative changes in the diabetic retina. High injection burden tied to the use of short acting therapies may lead to patient fatigue and lack of adherence, thereby limiting treatment efficacy. High injection burden and poor patient adherence can lead to increased amplitude and frequency of retinal fluctuations, which may lead to irreversible vision loss in some patients. The 0.19 mg fluocinolone acetonide implant can minimize retinal thickness fluctuations and reduce treatment burden through continuous and consistent treatment over 36 months. IOP elevation associated with the 0.19 mg fluocinolone acetonide implant is manageable in the majority of cases with topical IOP lowering therapy. Although below the consensus threshold, physicians were in high agreement that "the 0.19 mg fluocinolone acetonide implant may represent a viable treatment option to establish early baseline control of the underlying low-grade, chronic inflammatory disease in patients with DR/DME," and 93% of clinicians identified at least one clinical situation in which they would consider the use of steroids as baseline therapy. Key Abstract Findings: FAc provides reduction of RTV for up to 36 months: Reduced RTV is correlated to improved visual outcomes and better disease control; Eyes in which RTV was best controlled post-Fac, demonstrated significant gains in BCVA; The 0.19 mg FAc implant provides a durable treatment option that can reduce the burden of care for patients with DME.

08:14 EST Agilent deploys next generation explosive detection system at London's Heathrow - Agilent Technologies announced the deployment of the next generation of alarm resolution technology for checkpoints throughout London Heathrow airport, delivering advanced security and efficiency. The Insight200M from Agilent ensures increased safety on planes while improving passenger experience at airports. The ban on liquids in carry-on luggage was slowly lifted to allow baby food, medicinal items, and duty-free items, and there is a continuous shift to further simplify the experience at checkpoints while maintaining security. This shift has led to the adoption of new computed tomography X-ray screening technology in place of conventional X-ray systems. Heathrow has announced the rollout of the new CT security equipment throughout the airport over the next few years, however it requires an advanced alarm resolution system, such as the Insight200M, to be in place after the primary screening to resolve alarms and ensure safety while maintaining passenger satisfaction.

08:13 EST Incannex engages Eurofins to manufacture ReneCann therapeutic topical - Incannex Healthcare (IXHL) announced that it has engaged multinational contract development and manufacturing organisation Eurofins Scientific (ERFSF) to manufacture ReneCann therapeutic for topical applications. ReneCann is Incannex's proprietary topical cannabinoid formulation for treatment of dermatological conditions caused by disorders of the immune system, including vitiligo, psoriasis, and atopic dermatitis, otherwise known as eczema. The ReneCann formulation is commercially protected by granted and pending patents acquired by Incannex as part of the APIRx acquisition that was finalised in August of 2022. The unique formulation combines Cannabigerol and Cannabidiol. CBG is a non-psychoactive cannabinoid with potent anti-inflammatory properties. A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period. The study was conducted at the Maurits Clinic, The Netherlands, and led by a world-renowned dermatologist Dr. Marcus Meinardi, MD, PhD. In the study, ReneCann reduced disease scores in patients with each of the target skin diseases. Patients with vitiligo, psoriasis and atopic dermatitis were observed to experience improvements in symptoms of 10%, 33% and 22% respectively. The ReneCann Drug product that is produced by Eurofins CDMO will be used in clinical trials confirming the safety and therapeutic effect of ReneCann in vitiligo, psoriasis, and atopic dermatitis. Data on the quality and stability of ReneCann generated as part of this project at Eurofins will be used in the chemistry and manufacturing control modules of future regulatory packages with the US Food and Drug Administration. ReneCann also has the potential to be assessed for efficacy in other diseases where topical application may provide a benefit over conventional oral dosed cannabinoid formulations.

08:10 EST 9 Meters Biopharma announces design of its vurolenatide trial - 9 Meters Biopharma announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome, or SBS. The study design follows the company's successful End-of-Phase 2 meeting and incorporates input received from the FDA. The Phase 3 study, called VIBRANT 2, is a randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of vurolenatide 50 mg administered subcutaneously every two weeks for 12 weeks in adults with SBS. This international clinical study is designed to enroll approximately 105 patients with SBS and will be conducted in up to 50 clinical investigative sites in North America and Europe. The study population will include both SBS patients who meet the current parenteral support dependence definition and SBS patients who do not meet this PS requirement threshold. Patients with SBS suffer from severe malabsorption due to the lack of sufficient intestinal surface which results directly in severe and often debilitating fluid and nutritional losses in the form of chronic, recurrent diarrhea. This study will not only assess the degree to which vurolenatide can reduce weekly PS volume requirements, but it will also, for the first time in a large ambulatory study, assess the impact of vurolenatide on malabsorptive diarrhea as measured directly by total stool output (TSO) volume. To maximize the potential for vurolenatide to provide clinical benefit to the entire SBS population regardless of PS requirement, VIBRANT 2 incorporates two primary efficacy endpoints: 1) change from baseline in weekly PS volume which was the established primary efficacy outcome measure to support the approval of the GLP-2 agonist Gattex for treatment of SBS patients with a PS dependence; and 2) change from baseline in mean 24-hour TSO volume, which assesses TSO volume over the entire treatment period and incorporates specific FDA recommendations around the inclusion of nutrition and hydration parameters to help establish the clinical relevance of this novel endpoint. Reduction in PS and TSO are both important clinical signs indicative of patients' ability to absorb nutrients and fluids. It is planned that success on either primary efficacy endpoint can be the basis for a potential future New Drug Application submission for vurolenatide. In addition, an interim analysis is planned specifically for the PS-dependent patient population. When 50% of patients with PS dependence reach week 12, the interim analysis will determine whether an additional 12 weeks, which to date has been the regulatory predicate for GLP-2 agonists, will be required to assess safety and efficacy. All patients who complete the VIBRANT 2 double-blind treatment period will be eligible to enter an open-label extension study with the objective of assessing the long-term safety of vurolenatide for up to 12 months. U.S. Institutional Review Board approval has been secured, and study initiation is planned as early as the end of this year. Furthermore, several key features have been incorporated that we believe will optimize the ability to enroll the study, including utilizing a clinical research organization with specific experience executing late-stage clinical studies in SBS; securing up to 50 clinical study sites globally; and giving investigators the ability to enroll all SBS patients, regardless of PS status.

08:10 EST SciSparc regains compliance with Nasdaq minimum closing bid price rule - SciSparc reported the receipt of a formal notification from The Nasdaq Stock Market that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.

08:09 EST Store Capital says proxy advisory firms vote for GIC acquisition - Store Capital announced that leading independent proxy advisory firms Institutional Shareholder Services or ISS and Glass, Lewis have each recommended that stockholders vote "FOR" the previously announced all-cash acquisition of the Company by affiliates of GIC, a global institutional investor, and funds managed by Oak Street, a Division of Blue Owl, at the Company's upcoming Special Meeting of Stockholders scheduled for December 9.

08:09 EST Kratos Defense announces availability of OpenSpace Channelizer, Combiner - Kratos Defense & Security Solutions announced the general availability of its virtual OpenSpace Channelizer and Combiner for satellite ground operations. The products are used to split and combine digitized RF signals for more effective downlink and uplink, especially to support the advanced capabilities of next generation software-defined satellites and LEO constellations. For example, to support increasing customer demand or to address potential cases of interference, a high bandwidth signal from a software-defined satellite can be split into smaller signals and routed across the ground dynamically for service delivery or for RF analysis.

08:07 EST Aquestive Therapeutics announces publication of crossover food effect study - Aquestive Therapeutics announced the publication of a crossover food effect pharmacokinetic study of diazepam nasal spray in the peer-reviewed scientific journal Epilepsia. The study was sponsored by Aquestive in 2021 and conducted by an accredited independent clinical research organization. It was included by Aquestive as part of its New Drug Application for Libervant Buccal Film that was submitted to the U.S. Food & Drug Administration. The randomized, open-label crossover study compared equal doses of diazepam nasal spray after an overnight fast and after a standardized high-fat, high-calorie breakfast. Under fed conditions, the mean maximum plasma diazepam concentration was decreased by 48% and the overall diazepam exposure during the first four hours was reduced by 57% compared with fasted conditions. The time to maximum plasma concentration was 4.0 hours in the fed state, compared with 2.0 hours in the fasted state. At two hours post-dose, diazepam concentrations were greater than or equal to150 ng/mL for 100% of subjects when fasted and 30% when fed.

08:04 EST Regulus adds Rekha Garg and Claire Padgett to scientific leadership team - Regulus Therapeutics appointed Rekha Garg to Senior VP, Clinical Development and Regulatory, and Claire Padgett to Senior VP, Clinical Operations. The company also promoted Morgan Carlson to VP, Biology and Edmund Lee to VP, Translational Medicine. Lastly, Denis Drygin has stepped down from his role as Chief Scientific Officer to pursue other opportunities. Garg is a physician executive with over 20 years of experience in leadership roles in the biopharma industry. Before joining Regulus, she was Senior VP, Regulatory Affairs and Safety, at Sanifit Therapeutics. Prior to that, she was VP at Infinity Pharmaceuticals and served in multiple leadership roles in clinical development focused on regulatory affairs and risk management at Amgen and Eli Lilly. Padgett has more than 25 years of experience in clinical and development operations including Sanifit Therapeutics, Mirati Therapeutics, Mast Therapeutics, and Cylene Pharmaceuticals. Lee joined Regulus in 2013 from Hoffmann-La Roche and Millennium Pharmaceuticals. Carlson joined Regulus in 2020. He was previously a senior investigator at Novartis, and before that, an assistant professor of genetics and developmental biology at the University of Connecticut School of Medicine and Stem Cell Institute.

08:04 EST Novocure's Optune approved in Canada for recurrent glioblastoma - Novocure announced that Health Canada has approved Optune for the treatment of newly diagnosed and recurrent glioblastoma, GBM. GBM is the most common and one of the most aggressive forms of primary brain cancer. Optune is the first treatment for glioblastoma approved in Canada in over 12 years. Optune is a medical device that works by creating Tumor Treating Fields or TTFields, which are electric fields that disrupt cancer cell division. Optune delivers TTFields therapy to the region of the tumor. Optune is small and light, weighing 2.7 pounds. This makes Optune wearable and portable, so continuous treatment can be received almost anywhere. Globally, more than 25,000 patients have been treated with Optune, to date. "We're very happy that Health Canada has approved Optune for the treatment of GBM," said Jovan Antunovic, Country Manager of Novocure Canada. "We are grateful for the rapid and diligent review of our submission and for Health Canada's approval of Optune. This is an important achievement in order to bring our therapy to more patients throughout Canada who can benefit."

08:03 EST Bristol-Myers, Envisagenics announce research collaboration - Envisagenics, an Artificial Intelligence-driven biotechnology company that delivers therapies for RNA splicing diseases, announced a research collaboration agreement with Bristol Myers Squibb. The multi-year collaboration will leverage Envisagenics' SpliceCore AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.

08:02 EST COMSovereign Holding names David Knight as CEO - COMSovereign Holding announced that the Board of Directors has unanimously appointed David Knight as CEO, President, and a Director of the company on November 23. Knight was initially named interim CEO on September 7, following the departures of the company's CEO and its President.

07:52 EST Stack Capital invests $8M in Locus Robotics - Stack Capital Group (STCGF) invested $8M into preferred shares of Locus Robotics, a provider of enterprise robotics solutions, Stack Capital's investment was part of the recently announced $117M Series F funding which brought its valuation close to $2B and included Goldman Sachs Asset Management (GS), G2 Venture Partners, SuRo Capital, Next 47, Stafford Capital Partners, HESTA, Newton Investment Management North America, Gray's Creek Capital, Silicon Valley Bank, Hercules Capital, Inc., BOND, and Scale Venture Partners.

07:42 EST Skeena Resources announces additional mineralization at Eskay Creek - Skeena Resources announced the delineation of additional Rhyolite-hosted mineralization located in the 23 Zone as part of the recently completed 2022 regional and near mine exploration drilling campaigns at the Eskay Creek gold-silver Project. in the Golden Triangle of British Columbia. Infill drill holes SK-22-1092 and SK-22-1089 have successfully confirmed additional Rhyolite-hosted gold-silver mineralization from surface, intersecting 0.92 g/t Au, 12.5 g/t Ag over 79.97 m and 0.77 g/t Au, 7.9 g/t Ag over 29.90 m , respectively . These drill holes were collared from the same pad as previously reported drill hole SK-22-1090, which intersected 1.13 g/t Au, 6.6 g/t Ag over 96.02 m. The results highlighted above confirm the excellent downhole continuity of mineralization from the surface and have potential to positively impact the future open-pit strip ratio once the updated resource and engineering studies are completed. Results from additional nearby infill drill holes are pending and expected in the near future. "Exploration and infill drilling by Skeena continues to confirm and expand zones of mineralization in areas deemed non-prospective by previous operators. We are excited about the drill results we are seeing and expect a steady stream of new results in the coming weeks" commented Adrian Newton, Skeena's Director of Exploration.

07:36 EST Lordstown Motors announces Endurance achieved full homologation - Lordstown Motors announced that its Endurance full-size battery electric pickup truck has achieved full homologation. Certification has been received from both the EPA and CARB. These were the key conditions to start customer sales. FMVSS crash and non-crash testing were successfully completed. The first units, of its initial batch of 500, are leaving the Foxconn EV Ohio plant for customer delivery. As disclosed earlier, production volume will ramp slowly and accelerate as the company resolves supply chain constraints. "I am very proud of the Lordstown Motors and Foxconn EV Ohio team for their hard work, grit, and tenacity in achieving this milestone. We are very excited to start delivering vehicles to our commercial fleet customers. The EnduranceTM will provide benefits to customers that use their vehicles for work. It optimizes key attributes of traction and maneuverability - with our in-wheel hub motors, safety - with our five-star crash performance, and value in the segment," said Edward Hightower, Lordstown CEO and President.

07:34 EST KemPharm appoint Christopher Posner to board of directors - KemPharm (KMPH) announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Posner is currently the president and CEO of Cara Therapeutics (CARA), a commercial-stage biopharmaceutical company.

07:33 EST Conformis announces first procedure performed using Actera Hip System - Conformis announced that the first procedure with the company's new Actera Hip System has been performed. The new system is currently rolling out to select sites across the U.S., and the company anticipates the full commercial launch of Actera in mid-2023. Actera will feature several personalization options for surgeons to choose what best fits their patients, even for complex anatomies.

07:32 EST Context nominated CTIM-76 as candidate to target Claudin 6-positive cancers - Context Therapeutics announced the selection of CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 positive cancers, resulting from its research collaboration and licensing agreement with Integral Molecular. Context's lead candidate, CTIM-76, is a CLDN6 x CD3 bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding single-chain Fv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhance the safety profile. Preclinical studies suggest the potential for convenient dosing with low immunogenicity risk and manufacturing can be scalable to address the significant number of patients who are potentially eligible for CTIM-76 therapy. "This year has been marked by several exciting and significant milestones for Context, culminating in naming our lead CLDN6 clinical development candidate, CTIM-76, a bispecific antibody showing high selectivity for CLDN6," said Martin Lehr, CEO of Context Therapeutics. "We selected this bispecific based on the specificity which suggests its potential to address the need for potent therapeutic modalities for cancer without compromising patient safety. With the selection of CTIM-76 as our lead CLDN6 candidate, we are well-positioned to rapidly advance our clinical development plan in CLDN6-positive tumors including, but not limited to, ovarian cancer. We have initiated IND-enabling studies and expect to submit our Investigational New Drug Application for CTIM-76 to the U.S. Food and Drug Administration in Q1 2024."

07:26 EST Laser Photonics says FABTECH 2022 'yielded significant potential sales orders' - Laser Photonics announced that the FABTECH 2022 trade show yielded significant potential sales orders from new blue chip customers. Wayne Tupuola, CEO of LPC, commented: "This was the first trade show where we were able to showcase our new CleanTech Laser systems to current and potential customers and partners...and their level of interest was phenomenal. We received approximately 200 leads, with about 15% of them being new customers from Fortune 500, the U.S. Government and large global companies covering diverse industries, including oil and gas, military, railways, aerospace and defense OEMs, heavy equipment, marine, utilities, industrials and manufacturing and more. We conservatively estimate this expanded our pipeline for 2023 by $8 to $10 million for initial unit evaluation sales, which hopefully will lead to follow-on sales and deeper penetration within these organizations over time. I am very excited about our momentum heading into 2023."

07:20 EST Apollo Endosurgery to be acquired by Boston Scientific for $10.00 per share - Apollo Endosurgery (APEN) announced it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation (BSX) in an all-cash transaction with an enterprise value of approximately $615 million. This transaction has been unanimously approved by the Apollo Board of Directors. The acquisition price of $10.00 per share represents an approximate 67% premium to the closing price of Apollo's common stock on November 28, 2022 and the volume weighted average closing price of Apollo's common stock in the three months prior to announcement of the transaction. The transaction is subject to the satisfaction of customary closing conditions, including approval by a majority of Apollo's stockholders and applicable regulatory approval, and is expected to close in the first half of 2023. Certain stockholders representing 8.4% of Apollo's outstanding shares of common stock have agreed to vote their shares in favor of the transaction. Upon the completion of the transaction, Apollo will become a wholly-owned subsidiary of Boston Scientific.

07:16 EST Allakos announces publication of AK006 mechanism of action manuscript - Allakos announced the publication of "Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells," in Communications Biology. The publication describes the generation of Siglec-6 agonist monoclonal antibodies optimized for mast cell inhibition and their ability to suppress mast cell activity in pre-clinical models. Publication Details: The paper describes the identification of an epitope within the extracellular domain of Siglec-6 that allows for prolonged residence time on the mast cell surface. Key findings of the publication include: Identification of a Siglec-6 antibody that confers optimal mast cell inhibitory activity and ADCP function; dministration of this Siglec-6 antibody prevents systemic anaphylaxis in humanized mice with a single dose and reduces mast cell numbers with multiple doses; Engagement of Siglec-6 with an agonistic antibody induces formation of immunoregulatory synapses that recruit inhibitory signaling molecules that are required for potent mast cell inhibition. Allakos is currently completing IND-enabling studies and expects to begin in-human studies in the first half of 2023 in healthy volunteers and subsequently in patients with mast cell driven diseases.

07:13 EST ASP Isotopes in $27M supply pact with BRICEM for enriched Molybdenum-100 - ASP Isotopes announced that the Company has entered into 25-year supply agreement for highly enriched Molybdenum-100 with BRICEM or Beijing Research Institute of Chemical Engineering Metallurgy. Mo-100 is used in the preparation of radiopharmaceuticals used in nuclear medicine procedures to diagnose heart disease and cancer, to study organ structure and function, and to perform other important medical applications. The contract has a value of up to $27M per annum for 25 years and deliveries are scheduled to commence in July 2023. The Company now expects to begin delivering commercial quantities of Mo-100 from Q3 2023 versus previous guidance of "before 2024". The Company continues to have discussions with BRICEM regarding the production of other isotopes.

07:12 EST Renalytix announces publication highlighting KidneyIntelX test - Renalytix announces the publication of new real-world evidence in Primary Care and Community Health demonstrating the Company's KidneyIntelX bioprognostic test resulted in changed clinical decision making for patients in the early-stage of diabetic kidney disease being cared for within the Mount Sinai Health System's Population Health Ambulatory Pharmacy and Condition Management programs. The majority of patients were being treated by their primary care physician. Prediction of risk for kidney disease progression in early-stage DKD is often not assessed at the primary care level, resulting in more than 50,000 individuals per year with diabetes progressing to kidney failure, dialysis or a kidney transplant. By integrating an easily interpretable, accurate prognostic tool that assigns a risk score for progressive decline in kidney function, KidneyIntelX enables providers to act earlier to slow or stop the progression to kidney failure. Key points from the prospective study: The study was conducted in collaboration with the Mount Sinai Health System's Population Health Ambulatory Pharmacy and Condition Management programs and included 1,686 patients seen by 75 providers at 20 clinical sites. The RWE study demonstrated that patients with early-stage DKD and a high risk KidneyIntelX score received higher frequency of clinical management visits, introduction to guideline-recommended medications, and specialist referral for disease management compared to those who were identified as low or intermediate risk patients. The risk breakdown of the RWE study population was similar to the clinical validation cohort. Frequency of follow up visits: 53% of all KidneyIntelX high risk patients had a follow-up visit within 1-month of their KidneyIntelX test and 57% had action taken within 3-months, compared to 13% and 35%, respectively, for low risk patients. Medication management: When evaluating new or modified prescriptions for hypertension at six months, both ACEi and ARBs achieved a greater than 20% change in patients with hypertension in the high risk group vs. the low risk group. Medication management for use of SGLT2 inhibitors was even more pronounced; 25% of patients in the high risk group received new SGLT2i prescriptions vs. 7% in the low risk group, a 4.5-fold increase. Thus, KidneyIntelX enabled physicians to take guideline-recommended clinical actions in high risk, early stage diabetic kidney disease patients. Specialist referrals: New referrals by risk group were 6% for low risk, 12% intermediate risk and 15% high risk.

07:12 EST Femasys announces enrollment over 25% complete for FemaSeed de novo trial - Femasys announced that it has completed over 25% of its targeted enrollment in its FemaSeed de novo trial. FemaSeed is the first and only first-line approach in development designed to deliver sperm directly to where conception occurs. FemaSeed is a localized artificial insemination option that is also designed to be more affordable than assisted reproduction, such as in vitro fertilization. "Our strategy to focus on male factor infertility, where we believe FemaSeed could have the greatest impact, is proving to be a sound strategy as we expedite advancement of this clinical program," said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. "After announcing our updated strategic trial design only a month ago, we are thrilled to have reached over 25% of our targeted 214 FemaSeed cycles. Since it is estimated that 50% of all infertility cases can be attributed to male factor infertility, the Company believes that its FemaSeed product candidate could significantly benefit this population. We are proud to have hit multiple company milestones - both this quarter and last - and maintain continued momentum on all fronts with a strengthened management team as we advance our other programs: preparing for a pivotal study of FemBloc for permanent birth control followed by a confirmation test with FemChec early next year, and readying FemCath(TM) for the commercial marketplace before year end as well."

07:10 EST BiondVax reports results from preclinical in vivo study of NanoAb therapy - BiondVax Pharmaceuticals announced statistically significant efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody COVID-19 therapy. Study design: Using an industry-standard animal model for COVID-19 therapeutics and vaccines, the study compared weight loss in two groups of hamsters after infection with SARS-COV-2. The first group was treated with BiondVax's anti-COVID-19 NanoAb starting one day after being infected, while the second group was treated in the same manner but with saline serving as a placebo. Results: Compared to their weight immediately prior to infection, the control group's weight declined on average 12.01%, while the weight of the experimental group, which was administered BiondVax's NanoAb through inhalation, declined on average only 3.80%, a highly statistically significant result. The successful result was further supported by eight other tracked parameters, including heart rate and social behaviors, that indicated the group treated with inhaled NanoAbs experienced a milder and shorter illness. Amir Reichman, BiondVax's CEO, added, "Recent papers have highlighted the limitations of existing therapeutics, in particular Paxlovid (Pfizer) in at-risk populations, the absence of monoclonal antibodies that are highly effective against Omicron, and the need for new improved treatments to prevent severe disease. On top of that, there is a decrease in uptake of COVID-19 vaccinations and boosters. We believe our inhaled NanoAb therapeutic can serve this unmet need with a patient-friendly route of administration directly to the original source of infection." Next steps: This preclinical trial will continue in January 2023. The study will also evaluate safety parameters. In 2023, BiondVax will conduct a pre-clinical toxicity study as required by regulatory authorities for approval of human clinical trials. The Company will also scale-up its manufacturing processes to produce, at its GMP manufacturing site in Jerusalem, the NanoAbs for the first-in-human Phase 1/2a clinical trial in patients which is planned for Q4 2023.

07:09 EST Agra Ventures' Boundary Bay Cannabis receives $910,000 in purchase orders - Agra Ventures announces that the Propagation Services Canada Inc. joint venture of which it owns 70%, which is currently doing business as "Boundary Bay Cannabis" has received approximately $910,000 worth of purchase orders for its cannabis since August 31, 2022. The purchase orders were received from multiple parties and represent a total of over 725,000 grams of processed product. BBC's strategy continues to be the growing and selling of bulk cannabis on a wholesale basis to other licensed producers across Canada. The greenhouse complex in Delta, BC, within which the Joint Venture operates, provides a strong opportunity for BBC to be as competitive as possible in the Canadian cannabis industry. However, declining market prices; rising labour and energy expenses; and the ongoing high cost of maintaining regulatory compliance are making it difficult for licensed producers like BBC to operate unless Health Canada's review of the Cannabis Act yields some significant and imminent improvements.

07:07 EST Uranium Royalty Cameco to receive royalty proceeds from McArthur River mine - Uranium Royalty (UROY) announced that it has notified Orano Canada of URC's election to receive royalty proceeds from the recently re-started McArthur River mine through delivery of physical uranium. URC's royalty interest applies to Orano's 30.195% ownership interest in the McArthur River Project which is operated by Cameco (CCJ). Cameco currently plans to produce 15M pounds of U3O8 per year from the operations starting in 2024. URC further announces that it has completed the indirect acquisition of an existing royalty on the Dawn Lake project, located in the Athabasca Basin uranium district in Saskatchewan, Canada. URC applauds the re-start of the McArthur River mine. Cameco has disclosed that the world's largest, high-grade mine is planning to produce 15M pounds U3O8 per year starting in 2024. By electing to receive the royalty proceeds as physical uranium, it allows URC to control the sale of the attributed pounds in a disciplined, yet fully unhedged manner, focusing on providing the maximum value to shareholders. URC has acquired a sliding scale 10% to 20% NPI on a 7.5% share of overall uranium production from the Dawn Lake project lands. This royalty was previously subject to an option held by the company. The royalty was acquired through the company's acquisition of Reserve Minerals, the holder of the royalty, in consideration for $100,000. On November 9, Cameco announced that the first pounds of uranium ore produced from the McArthur River mine had been milled and packaged at the Key Lake mill, marking the initial production from McArthur River as it transitions back to normal operations. Cameco stated that McArthur River/Key Lake are expected to produce up to 2M pounds of uranium concentrate in 2022. It further disclosed that, starting in 2024, Cameco plans to produce 15M pounds of U3O8 per year from the operations. As of December 31, 2021, Cameco reported estimated: proven and probable mineral reserves of 393.9 Mlbs of U3O8 at an average grade of 6.58% U3O8; and measured and indicated resources, exclusive of reserves, of 9.0 Mlbs at an average grade of 2.26% U3O8 and inferred resources of 2.6 Mlbs at an average grade of 2.85% U3O8. URC's current royalty represents a 1% Gross Overriding Revenue Royalty on a 9.063% share of uranium production from the McArthur River project derived from Orano's current 30.195% production interest in the project. The Dawn Lake project is an early-stage exploration project located near Waterbury Lake in northern Saskatchewan, Canada approximately 700 km north of Saskatoon. The Dawn Lake property is operated by Cameco in partnership with Orano. The project grounds cover an area approximately between the McClean Lake mill and Cigar Lake mine in the Athabasca Basin uranium district. The Dawn Lake Royalty does not apply to the entirety of the project lands but covers approximately 99% of the project area and the Company believes that the Dawn Lake Royalty applies to substantially all areas of the project underlying the estimate of mineral resources. As of December 31, 2021, Cameco disclosed estimated indicated resources, exclusive of reserves, of 17.9 Mlbs at an average grade of 4.42% U3O8 and inferred resources of 1.0 Mlbs at an average grade of 1.02% U3O8, for the Tamarack deposit which is located in the Dawn Lake project area. The Dawn Lake project area also potentially covers the immediate strike extension of IsoEnergy's Hurricane deposit. In a news release on July 18, IsoEnergy disclosed estimated Indicated Mineral Resources for the Hurricane deposit of 48.61M lbs. of U3O8 based on 63,800 tons grading 34.5% U3O8 and Inferred Mineral Resources of 2.66M lbs. of U3O8 based on 54,300 tons grading 2.2% U3O8. For further clarity, the royalty does not cover the Hurricane resources as outlined above, only the potential western extension of the mineralized zone on the adjacent Dawn Lake project claims. In addition, the Dawn Lake project hosts several other significant historical mineralized areas, including the 11, 11A, 11B and 14 Zones of the Dawn Lake deposit, La Rocque Lake, Natona Bay and Thorburn Lake areas. These historical uranium occurrences do not have resources assigned to them by Cameco under the framework of NI-43-101. The Dawn Lake Royalty is a sliding scale 10% to 20% NPI on a 7.5% share of overall uranium production from the Dawn Lake project lands. The sliding scale royalty percentage for the Dawn Lake Royalty is based upon historical production and recoverable reserves of the combined Waterbury/Cigar Lake and Dawn Lake project lands, with the royalty rate having already achieved the maximum of 20% as the Cigar Lake mine has achieved such production and reserve threshold. The sliding royalty percentage will decrease to 10% after the combined production on both Waterbury/Cigar Lake and Dawn Lake projects reach a production hurdle of 200 Mlbs of U3O8. As a profit-based NPI interest, this royalty is calculated based upon generated revenue, with deductions for certain expenses and costs, which include cumulative expense accounts, including development costs. As such and given the significant total of expenditures on the project, the Dawn Lake Royalty will only generate revenue to the holder after these cumulative expenses are exhausted.

07:05 EST ALX Oncology appoints Scott Garland to board of directors - ALX Oncology Holdings announced the appointment of Scott Garland to its Board of Directors effective November 29, 2022. Garland is the CEO of PACT Pharma, an immuno-oncology company focused on developing neoantigen targeted T-cell therapies for solid tumors.

07:05 EST Atai Life Sciences names Sahil Kirpekar Chief Business Officer - Atai Life Sciences appointed Sahil Kirpekar to serve as the company's Chief Business Officer, effective immediately. Kirpekar joins atai after more than eight years at Otsuka Pharmaceutical, most recently as the Head of Business Development and Co-chair of the Global Business Development Committee. Prior to Otsuka, Kirpekar built and executed on commercial and market access strategies for biopharmaceutical companies globally as a strategy consultant at Double Helix Consulting. He also served as a market analyst for the World Health Organization and has co-founded a company building a drug delivery device focused on adherence.

07:05 EST Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer - Adicet Bio announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer. Dr. Boman will spearhead Adicet's regulatory strategy to further advance existing and new pipeline opportunities for the Company's gamma delta T cell platform. "We are incredibly excited to welcome Nancy to the Adicet team," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Her vast experience in successfully filing marketing applications for more than 15 products, including in hematologic malignancies, such as non-Hodgkin's lymphoma, is perfectly aligned with our plan to initiate a potentially pivotal program for ADI-001 in the first half of 2023. Nancy's leadership in building and expanding global regulatory operations particularly in the oncology field, including in solid tumors, is an asset to the team and positions us well as we expect to submit an IND application for ADI-925 in the second half of 2023 and potentially advance other pipeline programs, as disclosed in our recent R&D event, to regulatory submissions and clinical trials."

07:03 EST Tyra Biosciences doses first patient in Phase 1/2 study of Tyra-300 - Tyra Biosciences initiated its SURF301 Phase 1/2 clinical study, with first patient dosed with TYRA-300. TYRA-300, the company's lead product candidate stemming from its SNAP platform, is an oral, FGFR3-selective inhibitor for the treatment of metastatic urothelial carcinoma of the bladder and urinary tract. The Phase 1/2 clinical study is designed to determine the optimal and maximum tolerated doses and the recommended Phase 2 dose of TYRA-300, as well as to evaluate the preliminary antitumor activity of TYRA-300.

07:03 EST Aravive announces Fast Track Designation of batiraxcept for treatment of ccRCC - Aravive announced the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation to the company's lead program, batiraxcept, for treatment of patients with advanced or metastatic clear cell renal cell carcinoma, ccRCC, who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology-based and vascular endothelial growth factor tyrosine kinase inhibitor-based therapies. The Fast Track Designation was based on new data submitted to the agency from the P1b clear cell renal cell cancer study. "A review of the literature suggests that the clinical activity of cabozantinib is lower in those patients who have progressed following a VEGF-TKI-based therapy compared to patients who have progressed on IO or IO/IO therapy. Since preclinical data published by Xiao in 20191 observed that batiraxcept may restore TKI sensitivity, it makes sense that the combination of batiraxcept and cabozantinib may exhibit its greatest impact in those patients who have failed prior VEGF-TKI therapies," said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. "Understanding the P1b ccRCC data has allowed us to identify the most appropriate patient population in which to evaluate batiraxcept in combination with cabozantinib and potentially the quickest path to approval in this population with an unmet medical need."

07:01 EST Boston Scientific to acquire Apollo Endosurgery for $10.00 per share - Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Apollo Endosurgery (APEN) for a cash price of $10 per share, reflecting an enterprise value of approximately $615M. Apollo Endosurgery is expected to generate net sales of approximately $76M in 2022,5 as a result of the expected growth in its endoscopic suturing system franchise, including its OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System and X-Tack Endoscopic HeliX Tacking System. Boston Scientific expects to complete the transaction in the first half of 2023, subject to satisfaction of customary closing conditions. The impact to Boston Scientific's adjusted earnings per share is expected to be immaterial in 2023, and accretive thereafter. The impact to GAAP earnings per share is expected to be less accretive, or more dilutive, as the case may be, due to amortization expense and acquisition-related net charges.

06:33 EST Royal Bank of Canada to acquire HSBC Canada for C$13.5B in cash

06:14 EST AstraZeneca to acquire Neogene Therapeutics for $320M - AstraZeneca "announced an agreement to acquire Neogene Therapeutics, a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies that offer a novel cell therapy approach for targeting cancer. With a shared goal of bringing cell therapies to patients with solid tumours, Neogene's expertise in TCR-T discovery, development and manufacturing will strengthen AstraZeneca's ambition to transform outcomes for patients... AstraZeneca will acquire all outstanding equity of Neogene for a total consideration of up to $320M, on a cash and debt free basis. This will include an initial payment of $200M on deal closing, and a further up to $120M in both contingent milestones-based and non-contingent consideration. The transaction is expected to close in the first quarter of 2023, subject to customary closing conditions and regulatory clearances. The transaction does not impact AstraZeneca's financial guidance for 2022."

06:08 EST TransUnion's Q3 industry report shows growth in Canadian credit market - TransUnion released the findings of its Canada Q3 2022 Credit Industry Insights Report - CIIR -, which shows that more Canadian consumers are utilizing credit. Credit participation reached a new record high, with 27.9 million Canadians having active credit products with a total outstanding balance of $2.29T. This is a year-over-year increase of 7.9%, on a three-year compound annual growth rate of +6.4%. TransUnion also maps consumer credit market health with its Credit Industry Indicator, which rose 3.5 points YoY to 105.6 in September 2022, staying relatively steady following the Q2 2022 score of 103.8, after reaching a high of 110.8 in April this year. Credit participation increased mostly amongst those in Generation Z (born between 1995 and 2010) with a YoY increase of 20.9% as more Gen Z consumers entered the credit market and this cohort expanded the use of different products. "Rising CII levels generally indicate an improvement in the overall activity and health of the consumer credit market, which in the most recent quarter was primarily propelled by the strong credit activity due to balance growth and continued higher spend levels," said Matt Fabian, director of financial services research and consulting. "Credit performance remains relatively healthy compared to pre-pandemic levels, although the CII was offset somewhat by slowing credit demand in a high interest rate environment, with lenders also being more cautious in anticipation of continued macroeconomic headwinds," he added.

06:06 EST High Tide launches 'Cabana Elite' optional paid membership upgrade - High Tide is pleased to announce the launch of Cabana Elite, an optional paid membership upgrade for Cabana Club members. Starting immediately, customers can sign up for ELITE in-store and online at www.cannacabana.com. The company expects that ELITE will extend the Cabana Club membership program, attract new customers and instill even greater customer loyalty. The company anticipates that further discounts, benefits and promotions will be regularly added to ELITE.

06:03 EST Integral Ad Science appoints Khurrum Malik as chief marketing officer - Integral Ad Science (IAS) announced the appointment of Khurrum Malik as chief marketing officer, or CMO, effective immediately. Malik will accelerate market growth initiatives for IAS and lead its global marketing strategy. Malik will be based in New York and report directly to Yannis Dosios, chief commercial officer. Most recently, Malik was head of global business marketing at Spotify (SPOT).

05:18 EST Scuderia Ferrari team principle Mattia Binotto to resign - Ferrari announced that it has accepted the resignation of Mattia Binotto who will leave his role as Scuderia Ferrari Team Principal on December 31. Mattia Binotto said: "With the regret that this entails, I have decided to conclude my collaboration with Ferrari. I am leaving a company that I love, which I have been part of for 28 years, with the serenity that comes from the convinction that I have made every effort to achieve the objectives set. I leave a united and growing team. A strong team, ready, I'm sure, to achieve the highest goals, to which I wish all the best for the future. I think it is right to take this step at this time as hard as this decision has been for me. I would like to thank all the people at the Gestione Sportiva who have shared this journey with me, made up of difficulties but also of great satisfaction."